Takeda Owes AbbVie for Lupron Breach, as Trial on Damages Looms

Takeda Pharmaceutical Co. must face a second trial over its cancer drug supply agreement with an AbbVie Inc. unit, a Delaware Chancery Court judge ruled Wednesday, saying additional evidence will show how much Takeda’s contractual breaches cost its partner.

Vice Chancellor Sam Glasscock III sided with AbbVie, finding that Takeda—which manufactures the hormone therapy Lupron for it—was to blame for supply chain problems that led to ongoing shortages. Lupron is used to treat breast and prostate cancer, endometriosis, and gender dysphoria.

Glasscock—who previously bifurcated the case, holding a first trial over liability alone—said additional proceedings are needed to measure the ...